KK2260
Phase 1Small molecule
Kyowa Kirin Co., Ltd.KK2260 is one of 41 small molecule programs targeting Advanced or Metastatic Solid Tumors. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
80 competitors in Advanced or Metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Gemzar
Johnson & JohnsonPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Eloxatin
TevaPhase 2
Avastin
RochePhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Platinum
Bristol-Myers SquibbPhase 2
Mfolfox6
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KK2260. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company